| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 162 | 2023 | 5317 | 7.340 |
Why?
|
| General Surgery | 26 | 2017 | 326 | 5.320 |
Why?
|
| Surgical Oncology | 13 | 2021 | 190 | 5.090 |
Why?
|
| Skin Neoplasms | 114 | 2023 | 4654 | 4.970 |
Why?
|
| Sentinel Lymph Node Biopsy | 31 | 2023 | 1415 | 3.580 |
Why?
|
| Surgeons | 14 | 2024 | 519 | 3.580 |
Why?
|
| Burnout, Professional | 19 | 2012 | 205 | 3.520 |
Why?
|
| Medical Oncology | 18 | 2019 | 1423 | 3.410 |
Why?
|
| Oncologists | 6 | 2022 | 134 | 3.340 |
Why?
|
| Lymph Node Excision | 45 | 2023 | 1959 | 2.680 |
Why?
|
| Lymph Nodes | 30 | 2023 | 2967 | 2.400 |
Why?
|
| Physicians | 11 | 2022 | 882 | 2.140 |
Why?
|
| Job Satisfaction | 14 | 2012 | 122 | 1.930 |
Why?
|
| Specialties, Surgical | 6 | 2016 | 137 | 1.920 |
Why?
|
| Lymphatic Metastasis | 68 | 2023 | 4844 | 1.760 |
Why?
|
| Periodicals as Topic | 6 | 2017 | 338 | 1.740 |
Why?
|
| Neoplasm Staging | 76 | 2022 | 13658 | 1.730 |
Why?
|
| Publishing | 6 | 2018 | 220 | 1.650 |
Why?
|
| Neoplasms | 27 | 2023 | 15193 | 1.550 |
Why?
|
| Societies, Medical | 13 | 2020 | 1335 | 1.340 |
Why?
|
| Specialization | 4 | 2017 | 130 | 1.250 |
Why?
|
| Global Health | 8 | 2023 | 657 | 1.180 |
Why?
|
| History, 20th Century | 10 | 2020 | 574 | 1.110 |
Why?
|
| Humans | 265 | 2024 | 261506 | 1.090 |
Why?
|
| History, 21st Century | 9 | 2018 | 441 | 1.000 |
Why?
|
| Politics | 2 | 2021 | 74 | 0.960 |
Why?
|
| Population Health | 2 | 2024 | 51 | 0.930 |
Why?
|
| Stress, Psychological | 6 | 2012 | 1000 | 0.900 |
Why?
|
| Breast Neoplasms | 27 | 2021 | 15694 | 0.890 |
Why?
|
| Cancer Care Facilities | 4 | 2021 | 884 | 0.790 |
Why?
|
| Sentinel Lymph Node | 6 | 2023 | 216 | 0.790 |
Why?
|
| Prognosis | 72 | 2023 | 21713 | 0.770 |
Why?
|
| United States | 41 | 2021 | 15433 | 0.740 |
Why?
|
| Journal Impact Factor | 2 | 2017 | 40 | 0.710 |
Why?
|
| Writing | 3 | 2018 | 104 | 0.670 |
Why?
|
| Hospitals | 5 | 2024 | 485 | 0.660 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 280 | 0.650 |
Why?
|
| Manuscripts as Topic | 1 | 2018 | 3 | 0.640 |
Why?
|
| Medicine | 3 | 2008 | 137 | 0.640 |
Why?
|
| Retirement | 1 | 2018 | 22 | 0.630 |
Why?
|
| Mitotic Index | 3 | 2011 | 162 | 0.580 |
Why?
|
| Biomedical Research | 4 | 2019 | 806 | 0.570 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2020 | 10035 | 0.570 |
Why?
|
| Mastectomy | 8 | 2021 | 1534 | 0.560 |
Why?
|
| Skin Ulcer | 4 | 2013 | 77 | 0.550 |
Why?
|
| Workload | 4 | 2011 | 198 | 0.540 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 860 | 0.540 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2015 | 26 | 0.540 |
Why?
|
| Fellowships and Scholarships | 3 | 2019 | 390 | 0.540 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 383 | 0.530 |
Why?
|
| Physician Impairment | 2 | 2012 | 13 | 0.520 |
Why?
|
| Clinical Trials as Topic | 17 | 2015 | 3719 | 0.520 |
Why?
|
| Female | 116 | 2024 | 141928 | 0.520 |
Why?
|
| Age Factors | 9 | 2016 | 5377 | 0.510 |
Why?
|
| Survival Rate | 30 | 2020 | 12221 | 0.510 |
Why?
|
| Research Personnel | 2 | 2016 | 156 | 0.500 |
Why?
|
| Indocyanine Green | 1 | 2015 | 117 | 0.500 |
Why?
|
| Male | 95 | 2021 | 123000 | 0.500 |
Why?
|
| Radiology | 1 | 2020 | 434 | 0.490 |
Why?
|
| Benchmarking | 1 | 2016 | 273 | 0.490 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 264 | 0.470 |
Why?
|
| Certification | 1 | 2015 | 123 | 0.470 |
Why?
|
| Self Care | 3 | 2012 | 224 | 0.460 |
Why?
|
| Biopsy | 16 | 2010 | 3443 | 0.460 |
Why?
|
| Career Choice | 4 | 2011 | 232 | 0.460 |
Why?
|
| Health Promotion | 4 | 2017 | 502 | 0.460 |
Why?
|
| Proportional Hazards Models | 13 | 2011 | 4988 | 0.440 |
Why?
|
| Immunotherapy | 12 | 2018 | 3341 | 0.440 |
Why?
|
| Radiation Oncology | 1 | 2017 | 529 | 0.430 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 598 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 17 | 2021 | 3981 | 0.420 |
Why?
|
| Developing Countries | 4 | 2020 | 315 | 0.410 |
Why?
|
| Suicidal Ideation | 2 | 2011 | 207 | 0.410 |
Why?
|
| Mitosis | 2 | 2013 | 615 | 0.400 |
Why?
|
| Health Services Needs and Demand | 3 | 2018 | 244 | 0.390 |
Why?
|
| Malpractice | 1 | 2011 | 60 | 0.390 |
Why?
|
| Middle Aged | 82 | 2020 | 86204 | 0.380 |
Why?
|
| Efficiency | 1 | 2011 | 99 | 0.380 |
Why?
|
| Employment | 1 | 2011 | 129 | 0.370 |
Why?
|
| Health Status | 2 | 2022 | 590 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2018 | 1303 | 0.360 |
Why?
|
| Surgical Procedures, Operative | 4 | 2020 | 383 | 0.360 |
Why?
|
| Quality of Life | 11 | 2012 | 4532 | 0.350 |
Why?
|
| Anniversaries and Special Events | 2 | 2020 | 23 | 0.340 |
Why?
|
| Organ Transplantation | 1 | 2011 | 191 | 0.340 |
Why?
|
| Leadership | 2 | 2022 | 254 | 0.330 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2008 | 674 | 0.330 |
Why?
|
| Physician's Role | 3 | 2018 | 238 | 0.320 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2330 | 0.320 |
Why?
|
| Neoplasm Metastasis | 21 | 2009 | 5112 | 0.320 |
Why?
|
| Texas | 5 | 2024 | 6311 | 0.320 |
Why?
|
| Nipples | 1 | 2008 | 132 | 0.320 |
Why?
|
| Adult | 67 | 2019 | 77950 | 0.310 |
Why?
|
| Models, Statistical | 4 | 2010 | 1171 | 0.310 |
Why?
|
| Databases, Factual | 7 | 2018 | 2218 | 0.310 |
Why?
|
| Health Behavior | 1 | 2012 | 603 | 0.300 |
Why?
|
| Patient Preference | 1 | 2009 | 218 | 0.290 |
Why?
|
| Combined Modality Therapy | 24 | 2018 | 8865 | 0.290 |
Why?
|
| Thoracic Surgery | 1 | 2011 | 295 | 0.290 |
Why?
|
| International Cooperation | 2 | 2020 | 323 | 0.290 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 524 | 0.290 |
Why?
|
| Mastectomy, Segmental | 2 | 2009 | 1026 | 0.290 |
Why?
|
| Survival Analysis | 18 | 2010 | 9180 | 0.290 |
Why?
|
| Life Style | 4 | 2012 | 612 | 0.280 |
Why?
|
| Depression | 5 | 2011 | 1715 | 0.280 |
Why?
|
| Multivariate Analysis | 12 | 2015 | 4298 | 0.270 |
Why?
|
| Aged | 55 | 2020 | 70117 | 0.260 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 289 | 0.250 |
Why?
|
| Interleukin-2 | 13 | 1993 | 842 | 0.250 |
Why?
|
| Predictive Value of Tests | 9 | 2017 | 4892 | 0.250 |
Why?
|
| Eye Neoplasms | 1 | 2007 | 247 | 0.250 |
Why?
|
| Axilla | 11 | 2013 | 902 | 0.250 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 1085 | 0.240 |
Why?
|
| Attitude of Health Personnel | 5 | 2019 | 918 | 0.240 |
Why?
|
| Medical Errors | 3 | 2010 | 219 | 0.230 |
Why?
|
| Aged, 80 and over | 21 | 2016 | 29902 | 0.230 |
Why?
|
| Risk Factors | 16 | 2011 | 17523 | 0.230 |
Why?
|
| Patient Selection | 3 | 2008 | 2055 | 0.220 |
Why?
|
| Prospective Studies | 19 | 2018 | 12873 | 0.220 |
Why?
|
| Cross-Sectional Studies | 9 | 2018 | 4314 | 0.220 |
Why?
|
| Chi-Square Distribution | 4 | 2010 | 1323 | 0.220 |
Why?
|
| China | 3 | 2023 | 606 | 0.220 |
Why?
|
| Nomograms | 1 | 2005 | 313 | 0.220 |
Why?
|
| Bibliometrics | 1 | 2003 | 71 | 0.210 |
Why?
|
| Time Factors | 11 | 2014 | 12926 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 6 | 2013 | 3976 | 0.210 |
Why?
|
| Lymphocyte Activation | 9 | 1993 | 1688 | 0.200 |
Why?
|
| Postoperative Complications | 4 | 2011 | 5542 | 0.200 |
Why?
|
| Career Mobility | 2 | 2020 | 95 | 0.190 |
Why?
|
| North Carolina | 1 | 2021 | 125 | 0.190 |
Why?
|
| Population Surveillance | 4 | 2012 | 627 | 0.190 |
Why?
|
| DNA, Neoplasm | 3 | 1996 | 1910 | 0.190 |
Why?
|
| Universities | 1 | 2021 | 160 | 0.190 |
Why?
|
| Abdominal Neoplasms | 2 | 2001 | 231 | 0.190 |
Why?
|
| Foot Diseases | 2 | 1998 | 52 | 0.190 |
Why?
|
| New York City | 1 | 2020 | 74 | 0.180 |
Why?
|
| Regression Analysis | 9 | 2009 | 1546 | 0.180 |
Why?
|
| Personal Satisfaction | 2 | 2012 | 140 | 0.180 |
Why?
|
| Australia | 4 | 2010 | 225 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 4 | 1998 | 657 | 0.180 |
Why?
|
| Decision Making | 1 | 2007 | 1287 | 0.180 |
Why?
|
| Follow-Up Studies | 13 | 2018 | 14889 | 0.170 |
Why?
|
| Palliative Care | 6 | 2001 | 2037 | 0.170 |
Why?
|
| Colonic Neoplasms | 6 | 1992 | 1390 | 0.170 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2011 | 106 | 0.170 |
Why?
|
| Eligibility Determination | 1 | 2019 | 77 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5061 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.170 |
Why?
|
| Suicide | 3 | 2011 | 180 | 0.160 |
Why?
|
| Antineoplastic Agents | 8 | 2007 | 14289 | 0.160 |
Why?
|
| Treatment Outcome | 13 | 2015 | 32848 | 0.160 |
Why?
|
| Lipid A | 1 | 1998 | 30 | 0.160 |
Why?
|
| Ultrasonography | 2 | 2018 | 1863 | 0.160 |
Why?
|
| Skin | 6 | 2011 | 1259 | 0.160 |
Why?
|
| Leg | 2 | 1998 | 226 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 9 | 2021 | 992 | 0.150 |
Why?
|
| Retrospective Studies | 24 | 2023 | 37905 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2012 | 6869 | 0.150 |
Why?
|
| Mucous Membrane | 1 | 2018 | 271 | 0.150 |
Why?
|
| Rectal Neoplasms | 4 | 1990 | 1202 | 0.150 |
Why?
|
| Nail Diseases | 2 | 1994 | 40 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2020 | 289 | 0.150 |
Why?
|
| European Union | 1 | 2016 | 18 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 1996 | 771 | 0.140 |
Why?
|
| Sarcoma | 3 | 2000 | 1725 | 0.140 |
Why?
|
| Monocytes | 5 | 1993 | 788 | 0.140 |
Why?
|
| Monophenol Monooxygenase | 1 | 1996 | 59 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2013 | 2594 | 0.140 |
Why?
|
| Decision Trees | 3 | 2007 | 178 | 0.130 |
Why?
|
| Family Conflict | 2 | 2012 | 22 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 1998 | 575 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 1998 | 492 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 6207 | 0.130 |
Why?
|
| Depersonalization | 3 | 2012 | 15 | 0.130 |
Why?
|
| Cancer Vaccines | 2 | 1998 | 697 | 0.130 |
Why?
|
| Mammaplasty | 3 | 2008 | 780 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2017 | 414 | 0.130 |
Why?
|
| Interferon Type I | 2 | 1996 | 250 | 0.130 |
Why?
|
| Killer Cells, Natural | 4 | 1991 | 904 | 0.130 |
Why?
|
| History, 19th Century | 1 | 2015 | 154 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2403 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1999 | 882 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 436 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 1999 | 509 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 305 | 0.120 |
Why?
|
| Role | 2 | 1992 | 48 | 0.120 |
Why?
|
| Umbilicus | 1 | 1993 | 16 | 0.120 |
Why?
|
| Abdominal Muscles | 2 | 1993 | 68 | 0.120 |
Why?
|
| Floxuridine | 2 | 1983 | 38 | 0.120 |
Why?
|
| Professional Practice | 2 | 2011 | 82 | 0.120 |
Why?
|
| World Health Organization | 1 | 2015 | 316 | 0.120 |
Why?
|
| Netherlands | 2 | 2006 | 83 | 0.120 |
Why?
|
| Mass Screening | 3 | 2005 | 1509 | 0.120 |
Why?
|
| Silicones | 1 | 1993 | 54 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 585 | 0.110 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 672 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2011 | 5687 | 0.110 |
Why?
|
| Infusions, Intra-Arterial | 2 | 1983 | 171 | 0.110 |
Why?
|
| Uncertainty | 1 | 2015 | 320 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 671 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 1995 | 297 | 0.110 |
Why?
|
| Incidence | 6 | 2015 | 5673 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 1998 | 675 | 0.110 |
Why?
|
| Physicians, Women | 2 | 2012 | 105 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 276 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 1992 | 1016 | 0.110 |
Why?
|
| Surgical Flaps | 3 | 1993 | 927 | 0.110 |
Why?
|
| Work Schedule Tolerance | 2 | 2012 | 53 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2002 | 1363 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Young Adult | 5 | 2015 | 21445 | 0.100 |
Why?
|
| Private Sector | 1 | 2011 | 32 | 0.100 |
Why?
|
| Alcohol-Related Disorders | 1 | 2012 | 40 | 0.100 |
Why?
|
| Private Practice | 1 | 2011 | 31 | 0.100 |
Why?
|
| Conflict of Interest | 2 | 2002 | 98 | 0.100 |
Why?
|
| Dacarbazine | 5 | 1994 | 485 | 0.100 |
Why?
|
| Prostheses and Implants | 1 | 1993 | 295 | 0.100 |
Why?
|
| Night Care | 1 | 2010 | 2 | 0.100 |
Why?
|
| Women, Working | 1 | 2010 | 15 | 0.100 |
Why?
|
| Marriage | 1 | 2010 | 45 | 0.100 |
Why?
|
| After-Hours Care | 1 | 2010 | 9 | 0.100 |
Why?
|
| Sex Factors | 5 | 2009 | 2139 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2011 | 118 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3890 | 0.100 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 58 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 2231 | 0.090 |
Why?
|
| Health Surveys | 1 | 2012 | 402 | 0.090 |
Why?
|
| Internship and Residency | 2 | 2019 | 1375 | 0.090 |
Why?
|
| Random Allocation | 8 | 1988 | 703 | 0.090 |
Why?
|
| Lung Neoplasms | 5 | 2022 | 11538 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 3203 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 1993 | 402 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2010 | 495 | 0.090 |
Why?
|
| Vaccinia virus | 3 | 1998 | 79 | 0.090 |
Why?
|
| Internationality | 1 | 2010 | 208 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2009 | 133 | 0.090 |
Why?
|
| Training Support | 1 | 1989 | 29 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 10 | 2014 | 4367 | 0.090 |
Why?
|
| Pathology, Surgical | 1 | 2009 | 81 | 0.080 |
Why?
|
| Adolescent | 15 | 2009 | 31252 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 1988 | 24 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2009 | 233 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 1991 | 374 | 0.080 |
Why?
|
| Lymphocytes | 3 | 1990 | 1234 | 0.080 |
Why?
|
| Data Collection | 2 | 2010 | 620 | 0.080 |
Why?
|
| Comorbidity | 2 | 2012 | 2352 | 0.080 |
Why?
|
| Cause of Death | 1 | 2011 | 752 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 1085 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 649 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1989 | 208 | 0.080 |
Why?
|
| Research | 2 | 1992 | 415 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 3441 | 0.080 |
Why?
|
| Consensus | 3 | 2018 | 978 | 0.080 |
Why?
|
| Extremities | 4 | 2000 | 303 | 0.080 |
Why?
|
| World War II | 1 | 2006 | 6 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 482 | 0.070 |
Why?
|
| Disease-Free Survival | 8 | 2000 | 10001 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 1990 | 673 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 4 | 1995 | 2326 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 1 | 1986 | 87 | 0.070 |
Why?
|
| Military Medicine | 1 | 2006 | 53 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2007 | 179 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2009 | 348 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2015 | 15862 | 0.070 |
Why?
|
| Mentors | 1 | 2008 | 203 | 0.070 |
Why?
|
| New Zealand | 1 | 2005 | 60 | 0.070 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10331 | 0.070 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 748 | 0.070 |
Why?
|
| Methods | 4 | 1990 | 189 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2006 | 124 | 0.070 |
Why?
|
| Anus Neoplasms | 1 | 1990 | 411 | 0.070 |
Why?
|
| Bacterial Vaccines | 2 | 1984 | 103 | 0.070 |
Why?
|
| Physical Examination | 2 | 2005 | 299 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2006 | 205 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7548 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 698 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2007 | 4971 | 0.060 |
Why?
|
| Glycoproteins | 1 | 1989 | 747 | 0.060 |
Why?
|
| Recombinant Proteins | 6 | 1997 | 2927 | 0.060 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 607 | 0.060 |
Why?
|
| Cost of Illness | 2 | 2019 | 498 | 0.060 |
Why?
|
| Stomach Diseases | 1 | 1985 | 62 | 0.060 |
Why?
|
| Ploidies | 2 | 1996 | 248 | 0.060 |
Why?
|
| Viral Vaccines | 3 | 1998 | 304 | 0.060 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 1991 | 169 | 0.060 |
Why?
|
| Exercise | 1 | 2012 | 1183 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 2 | 1995 | 63 | 0.060 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 2 | 1995 | 58 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2008 | 557 | 0.060 |
Why?
|
| Length of Stay | 2 | 1988 | 1900 | 0.060 |
Why?
|
| Prevalence | 4 | 2012 | 3260 | 0.060 |
Why?
|
| Breast | 1 | 1990 | 1344 | 0.060 |
Why?
|
| Antigens, Neoplasm | 4 | 1998 | 1506 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2000 | 299 | 0.060 |
Why?
|
| Liver Neoplasms | 4 | 1983 | 4557 | 0.060 |
Why?
|
| Prostaglandins E | 1 | 1982 | 23 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1990 | 1146 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 915 | 0.060 |
Why?
|
| Kidney Neoplasms | 3 | 1995 | 3022 | 0.060 |
Why?
|
| T-Lymphocytes | 3 | 1991 | 3869 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 4 | 1998 | 1763 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 1999 | 660 | 0.050 |
Why?
|
| Clinical Protocols | 3 | 2009 | 467 | 0.050 |
Why?
|
| Corynebacterium | 1 | 1982 | 13 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 4975 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 1991 | 3001 | 0.050 |
Why?
|
| Risk | 5 | 2010 | 1972 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1994 | 212 | 0.050 |
Why?
|
| Intraoperative Care | 2 | 2000 | 259 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 5437 | 0.050 |
Why?
|
| Smallpox Vaccine | 2 | 1998 | 43 | 0.050 |
Why?
|
| Health Policy | 1 | 2023 | 291 | 0.050 |
Why?
|
| Child | 6 | 2007 | 29154 | 0.050 |
Why?
|
| Personnel Management | 1 | 2020 | 8 | 0.050 |
Why?
|
| Hodgkin Disease | 2 | 1989 | 1429 | 0.050 |
Why?
|
| Lymphoma | 1 | 1989 | 1467 | 0.050 |
Why?
|
| Nails | 1 | 2020 | 36 | 0.050 |
Why?
|
| Research Support as Topic | 3 | 2002 | 122 | 0.050 |
Why?
|
| Technetium Compounds | 1 | 1999 | 12 | 0.040 |
Why?
|
| Antimony | 1 | 1999 | 9 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2008 | 1656 | 0.040 |
Why?
|
| Staff Development | 1 | 2020 | 61 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 104 | 0.040 |
Why?
|
| Gamma Cameras | 1 | 1999 | 40 | 0.040 |
Why?
|
| Alcoholism | 2 | 2012 | 285 | 0.040 |
Why?
|
| Lymphoscintigraphy | 1 | 1999 | 35 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 170 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 7551 | 0.040 |
Why?
|
| Cefonicid | 1 | 1998 | 2 | 0.040 |
Why?
|
| Propionibacterium acnes | 2 | 1991 | 25 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2011 | 7226 | 0.040 |
Why?
|
| Immunity, Active | 1 | 1998 | 14 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 1996 | 3033 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 270 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 104 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 673 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1998 | 148 | 0.040 |
Why?
|
| Thorax | 1 | 1999 | 213 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 9244 | 0.040 |
Why?
|
| Carcinoma | 2 | 1992 | 2578 | 0.040 |
Why?
|
| Immunoglobulin G | 3 | 1998 | 1021 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1990 | 159 | 0.040 |
Why?
|
| Groin | 2 | 1998 | 74 | 0.040 |
Why?
|
| Kinetics | 3 | 1989 | 2049 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 1999 | 250 | 0.040 |
Why?
|
| Clone Cells | 4 | 1994 | 555 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 181 | 0.040 |
Why?
|
| Health Education | 1 | 2019 | 309 | 0.040 |
Why?
|
| Intention | 1 | 2017 | 109 | 0.040 |
Why?
|
| Antigens, CD | 3 | 1998 | 1385 | 0.040 |
Why?
|
| Alabama | 3 | 1992 | 39 | 0.040 |
Why?
|
| Public Health | 1 | 2019 | 299 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2020 | 442 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2019 | 1270 | 0.040 |
Why?
|
| Registries | 3 | 2017 | 2170 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 1989 | 2278 | 0.040 |
Why?
|
| Indomethacin | 2 | 1989 | 91 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1998 | 621 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 1988 | 445 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 600 | 0.030 |
Why?
|
| Reoperation | 1 | 2000 | 1382 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 289 | 0.030 |
Why?
|
| Selection Bias | 1 | 1995 | 50 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 3 | 1992 | 186 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.030 |
Why?
|
| Surgical Wound Infection | 3 | 1998 | 450 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 1990 | 167 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 3 | 1980 | 356 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 1980 | 713 | 0.030 |
Why?
|
| Algorithms | 3 | 2007 | 3890 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2007 | 16273 | 0.030 |
Why?
|
| Alkaline Phosphatase | 2 | 1985 | 207 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1995 | 709 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 524 | 0.030 |
Why?
|
| Cell Communication | 3 | 1994 | 509 | 0.030 |
Why?
|
| Polymyalgia Rheumatica | 1 | 1993 | 4 | 0.030 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1993 | 70 | 0.030 |
Why?
|
| Tissue Expansion Devices | 1 | 1993 | 62 | 0.030 |
Why?
|
| Connective Tissue Diseases | 1 | 1993 | 50 | 0.030 |
Why?
|
| Gels | 1 | 1993 | 105 | 0.030 |
Why?
|
| Computers | 2 | 1986 | 141 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1992 | 52 | 0.030 |
Why?
|
| Contract Services | 2 | 2002 | 7 | 0.030 |
Why?
|
| Physician Executives | 1 | 1992 | 40 | 0.030 |
Why?
|
| Ethics, Professional | 2 | 2002 | 26 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1999 | 1648 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Life Change Events | 1 | 2012 | 83 | 0.030 |
Why?
|
| Vaccines | 1 | 1997 | 389 | 0.030 |
Why?
|
| Authorship | 2 | 2002 | 53 | 0.030 |
Why?
|
| Drug Industry | 2 | 2002 | 88 | 0.030 |
Why?
|
| Quality Control | 2 | 1983 | 457 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2000 | 2054 | 0.030 |
Why?
|
| Arizona | 1 | 2011 | 32 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 1000 | 0.030 |
Why?
|
| Infant | 1 | 2007 | 13310 | 0.030 |
Why?
|
| Minnesota | 1 | 2011 | 93 | 0.020 |
Why?
|
| Florida | 1 | 2011 | 113 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1997 | 1529 | 0.020 |
Why?
|
| Job Description | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cytokines | 4 | 1994 | 2809 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1990 | 49 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 227 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Edema | 1 | 1992 | 267 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 1992 | 309 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 306 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 657 | 0.020 |
Why?
|
| Neoplasm Transplantation | 3 | 1989 | 1519 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1988 | 461 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2010 | 102 | 0.020 |
Why?
|
| Ear Neoplasms | 1 | 1990 | 59 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1975 | 691 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 1989 | 1082 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 430 | 0.020 |
Why?
|
| Forecasting | 1 | 1992 | 694 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 1990 | 84 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2014 | 710 | 0.020 |
Why?
|
| Fingers | 1 | 1990 | 120 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1998 | 2576 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1975 | 755 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 1993 | 487 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5159 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 4744 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 71 | 0.020 |
Why?
|
| Budgets | 1 | 1989 | 25 | 0.020 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1988 | 14 | 0.020 |
Why?
|
| Anal Canal | 1 | 1990 | 238 | 0.020 |
Why?
|
| Fees and Charges | 1 | 1988 | 16 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 1983 | 2307 | 0.020 |
Why?
|
| Cost Control | 1 | 1988 | 48 | 0.020 |
Why?
|
| Cells, Cultured | 4 | 1991 | 5637 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1988 | 91 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1988 | 84 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1991 | 354 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 1031 | 0.020 |
Why?
|
| Family | 1 | 2012 | 736 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1991 | 399 | 0.020 |
Why?
|
| Brain Neoplasms | 3 | 1996 | 4849 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2011 | 227 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 6009 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 3154 | 0.020 |
Why?
|
| Rectum | 1 | 1990 | 467 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 5 | 1994 | 5395 | 0.020 |
Why?
|
| Maryland | 1 | 2007 | 48 | 0.020 |
Why?
|
| Epitopes | 1 | 1990 | 685 | 0.020 |
Why?
|
| Double-Blind Method | 3 | 1998 | 2588 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 250 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 231 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2009 | 256 | 0.020 |
Why?
|
| Vaccines, Combined | 2 | 1997 | 39 | 0.020 |
Why?
|
| Fluorouracil | 1 | 1991 | 1944 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 1989 | 368 | 0.020 |
Why?
|
| Palpation | 1 | 1985 | 49 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1996 | 6150 | 0.020 |
Why?
|
| Drainage | 1 | 1988 | 416 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 573 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 415 | 0.020 |
Why?
|
| Nurses | 1 | 1986 | 80 | 0.020 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2007 | 255 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1993 | 1411 | 0.020 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1986 | 142 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 1225 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1984 | 47 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 636 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1990 | 795 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 690 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1053 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 1983 | 25 | 0.010 |
Why?
|
| Laparotomy | 1 | 1985 | 211 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1991 | 3005 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1983 | 173 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1987 | 750 | 0.010 |
Why?
|
| Interferons | 1 | 1984 | 291 | 0.010 |
Why?
|
| Interleukin-4 | 2 | 1994 | 284 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1983 | 418 | 0.010 |
Why?
|
| Bilirubin | 1 | 1983 | 221 | 0.010 |
Why?
|
| Carbazoles | 1 | 1982 | 87 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1989 | 1039 | 0.010 |
Why?
|
| Brain | 1 | 1996 | 4113 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1989 | 2315 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1983 | 129 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2001 | 61 | 0.010 |
Why?
|
| Neck Dissection | 1 | 1983 | 290 | 0.010 |
Why?
|
| Liposomes | 2 | 1995 | 684 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1991 | 6100 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1983 | 240 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1982 | 208 | 0.010 |
Why?
|
| Colectomy | 1 | 1983 | 288 | 0.010 |
Why?
|
| Kidney | 1 | 1990 | 2146 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| CD8 Antigens | 2 | 1992 | 170 | 0.010 |
Why?
|
| CD4 Antigens | 2 | 1992 | 170 | 0.010 |
Why?
|
| Abdomen | 1 | 1983 | 332 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1983 | 319 | 0.010 |
Why?
|
| Hernia, Ventral | 1 | 1983 | 159 | 0.010 |
Why?
|
| Neoplasm Proteins | 2 | 1989 | 3230 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1996 | 8873 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 4078 | 0.010 |
Why?
|
| Sentinel Surveillance | 1 | 1999 | 34 | 0.010 |
Why?
|
| Melanins | 1 | 1978 | 50 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1983 | 548 | 0.010 |
Why?
|
| Research Design | 1 | 1986 | 1544 | 0.010 |
Why?
|
| Phenotype | 4 | 1991 | 6295 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1998 | 275 | 0.010 |
Why?
|
| Cell Division | 2 | 1993 | 2489 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1979 | 699 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1989 | 875 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 1997 | 30 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1980 | 349 | 0.010 |
Why?
|
| Immunophenotyping | 2 | 1991 | 1681 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 2803 | 0.010 |
Why?
|
| Recurrence | 2 | 1998 | 4758 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 1382 | 0.010 |
Why?
|
| Cell Movement | 2 | 1995 | 2466 | 0.010 |
Why?
|
| Cadaver | 1 | 1975 | 237 | 0.010 |
Why?
|
| Proteinuria | 1 | 1975 | 155 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 1995 | 210 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 945 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1994 | 138 | 0.010 |
Why?
|
| Vinblastine | 1 | 1994 | 453 | 0.010 |
Why?
|
| New South Wales | 1 | 1992 | 8 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1997 | 889 | 0.010 |
Why?
|
| Mice | 3 | 1989 | 34495 | 0.010 |
Why?
|
| Immunosuppressive Agents | 2 | 1988 | 1375 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1991 | 84 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 1992 | 159 | 0.010 |
Why?
|
| Life Tables | 1 | 1991 | 120 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1993 | 327 | 0.010 |
Why?
|
| Staphylococcal Protein A | 1 | 1990 | 18 | 0.010 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1990 | 16 | 0.010 |
Why?
|
| Sepharose | 1 | 1990 | 32 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1975 | 834 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 122 | 0.010 |
Why?
|
| Cell Count | 1 | 1991 | 508 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1990 | 101 | 0.010 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 1990 | 34 | 0.010 |
Why?
|
| Necrosis | 1 | 1991 | 580 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1994 | 966 | 0.010 |
Why?
|
| Plasma | 1 | 1990 | 158 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1990 | 383 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1990 | 314 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1990 | 294 | 0.010 |
Why?
|
| Biological Factors | 1 | 1989 | 45 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 1033 | 0.010 |
Why?
|
| Arm | 1 | 1990 | 147 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1975 | 2843 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1989 | 65 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 1989 | 82 | 0.010 |
Why?
|
| Myeloma Proteins | 1 | 1988 | 28 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1989 | 231 | 0.010 |
Why?
|
| Viscera | 1 | 1989 | 81 | 0.010 |
Why?
|
| Hybridomas | 1 | 1988 | 75 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1988 | 72 | 0.010 |
Why?
|
| Animals | 3 | 1989 | 59536 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1988 | 135 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1994 | 1294 | 0.010 |
Why?
|
| Remission Induction | 1 | 1994 | 3569 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 1062 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 1618 | 0.000 |
Why?
|
| Antibodies, Neoplasm | 1 | 1989 | 259 | 0.000 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 238 | 0.000 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1990 | 582 | 0.000 |
Why?
|
| Extracellular Matrix | 1 | 1990 | 554 | 0.000 |
Why?
|
| Interferon-gamma | 1 | 1991 | 1144 | 0.000 |
Why?
|
| Collagen | 1 | 1990 | 752 | 0.000 |
Why?
|
| Cisplatin | 1 | 1994 | 2432 | 0.000 |
Why?
|
| Melphalan | 1 | 1990 | 834 | 0.000 |
Why?
|
| Receptors, Immunologic | 1 | 1988 | 309 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1992 | 1242 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1986 | 471 | 0.000 |
Why?
|
| Polypropylenes | 1 | 1983 | 25 | 0.000 |
Why?
|
| Tensile Strength | 1 | 1983 | 73 | 0.000 |
Why?
|
| Polyglycolic Acid | 1 | 1983 | 34 | 0.000 |
Why?
|
| Nerve Tissue Proteins | 1 | 1990 | 1491 | 0.000 |
Why?
|
| Sutures | 1 | 1983 | 86 | 0.000 |
Why?
|
| Mice, Nude | 1 | 1989 | 4307 | 0.000 |
Why?
|